1. Pink Sheet
  2. >>Market Access
  3. >>Health Technology Assessment

Industry Demands Rethink Of German HTA Data Requirements

 
• By Francesca Bruce

The pharmaceutical industry is calling for more flexible evidence requirements for health technology assessments in Germany after the country’s HTA body, IQWiG, claimed that too many new products entering the market lack additional benefit.

Germany
Pharma wants German HTA to be more flexible. • Source: Shutterstock

Germany’s benefit assessment system for new drugs needs to be more flexible in terms of the evidence that it requires, say R&D-based pharmaceutical industry associations. The comments come in response to findings by the German health technology assessment (HTA) body, IQWiG, that more than half the new drugs entering the country’s health care system offer no additional benefit compared to existing therapies.

New post-launch evidence generation tools could help prove a new drug’s additional benefit, said Alexander Natz, secretary general of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

Industry Criticizes Dutch Decision To Slash PARP Inhibitor Reimbursement

 
• By Francesca Bruce

ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.

Canada Unveils Draft List of Essential Drugs For Universal Pharmacare

 
• By Neena Brizmohun

The list of essential prescription drugs and related products will shape Canada’s first national formulary for the country’s universal pharmacare program.

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla

 
• By Neena Brizmohun

Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.

More from Market Access